ALSO NOTED: CSL Behring wins OK for new indication; Helix BioPharma touts new data; and much more...

> The FDA has announced its approval for an additional indication for CSL Behring's Rhophylac, an anti-D Rh immunoglobulin. Release

> Canada's Helix BioPharma announced positive results from its phase II clinical study of its Topical Interferon Alpha-2b in women with human papilloma virus induced low-grade cervical lesions. Release

> Heralding a major milestone in the four-year-old collaboration between India's Ranbaxy and GlaxoSmithKline, researchers say they have identified a respiratory drug candidate for pre-clinical development. In the pact, Ranbaxy will be responsible for Phase I and II studies while GSK will take over all subsequent research. Report

> Looking to enhance its reputation in microbiology, BioMerieux is buying Spain's BioMedics for $5.5 million. Report

> Abbott Laboratories has asked U.S. and European regulators to approve Humira for moderate to severe chronic plaque psoriasis. Report

> GSK has submitted Tykerb for approval in Japan against breast cancer. Report

> Japan's Daiichi Sankyo is transferring commercial rights to the anti-clotting drug Panaldine to France's Sanofi-Aventis. Report

And Finally… Drug companies spent $155 million on federal lobbying in the 18 months through June of last year, according to a report from the Center for Public Integrity. Much of that money was spent passing a provision that bars regulators from negotiating drug prices for the Medicare pharmacy benefit. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.